Oppenheimer lowered the firm’s price target on Idex Corp. (IEX) to $210 from $212 and keeps an Outperform rating on the shares. The firm recently toured the company’s Rochester, NY Life Sciences Optics Center of Excellence, also meeting with Health & Science Technologies Group Executive Tara Tereso. Oppenheimer came away with a greater appreciation of IH&S differentiation and growth potential, as well as a stronger understanding of Idex’s integrated growth strategy and related value-creation runway.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IEX: